You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Successful Allogeneic Bone Marrow Transplantation Using Reduced Doses of Cyclophosphamide and Fludarabine Associated to Granulocyte Transfusions in a Patient With Severe Aplastic Anemia Complicated by an Invasive Aspergillosis of Sinuses and a Rhizopus Gingivitis

Ladeb, Saloua MD*; Lakhal, Amel MD*; Barhoumi, Walid MD*; Abdejlil, Nour Ben MD*; Chelli-Bouaziz, Mouna MD; Salah, Mamia Ben MD; Torjman, Lamia MD*; Kallel, Kalthoum MD§; Maammar, Mongi MD; Othman, Tarek Ben MD*

Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31826e7f48
Case Reports
Abstract

Abstract: Mucormycosis and invasive aspergillosis complicating severe aplastic anemia are aggressive infections associated to high mortality in the lack of rapid neutrophil and monocyte recovery. We report a child who had severe aplastic anemia complicated by sinusal invasive aspergillosis and by Rhizopus arrhizus, probably breakthrough gingivitis, which occurred under voriconazole. She underwent a rescue sibling bone marrow transplantation considered as the only chance for survive. Use of fludarabine-containing conditioning, granulocyte colony-stimulating factor allowed rapid engraftment. Granulocyte transfusion and use of amphotericin B–voriconazole association permitted infection control, which was favored by immune recovery.

Author Information

From the *Bone Marrow Unit, Centre National de Greffe de Moelle Osseuse (CNGMO), Tunis, Tunisia; †Radiology Department, Institut M T Kassab, Ksar-Said, Tunisia; ‡Department of Otorhinolaryngology, Hôpital Charles Nicole, Tunis, Tunisia; §Department of Mycology, Hôpital La Rabta, Tunis, Tunisia and ∥Apheresis Unit, Centre National de Transfusion sanguine, Tunis, Tunisia.

Correspondence to: Saloua Ladeb, MD, Centre National de Greffe de Moelle Osseuse, rue Jebel Lakhdhar, 1006 Bab Saadoun, Tunis, Tunisia. E-mail: ladebsaloua@gnet.tn.

The authors have no funding or conflicts of interest to disclose.

© 2013 by Lippincott Williams & Wilkins.